Here, we describe the use of proactive therapeutic drug monitoring (TDM) to individualize the optimal timing of drug injections in 16 adult patients with chronic osteoarticular infections receiving a median of 7 injections of dalbavancin (up to 12 injections in 15 months). Dalbavancin injections were repeated at medians of 39-47 days, with infusion intervals ranging from 26 to 69 days. TDM can facilitates a precise, targeted use of dalbavancin for infections requiring prolonged treatments.
Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/periprosthetic joint infections / D. Cattaneo, M. Fusi, L. Galli, C. Genovese, R. Giorgi, M. Matone, S. Merli, M. Colaneri, A. Gori. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 1098-6596. - 68:4(2024 Apr 03), pp. e0002324.1-e0002324.5. [10.1128/aac.00023-24]
Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/periprosthetic joint infections
D. CattaneoPrimo
;M. FusiSecondo
;C. Genovese;R. Giorgi;M. Matone;S. Merli;M. ColaneriPenultimo
;A. GoriUltimo
2024
Abstract
Here, we describe the use of proactive therapeutic drug monitoring (TDM) to individualize the optimal timing of drug injections in 16 adult patients with chronic osteoarticular infections receiving a median of 7 injections of dalbavancin (up to 12 injections in 15 months). Dalbavancin injections were repeated at medians of 39-47 days, with infusion intervals ranging from 26 to 69 days. TDM can facilitates a precise, targeted use of dalbavancin for infections requiring prolonged treatments.File | Dimensione | Formato | |
---|---|---|---|
Proactive therapeutic monitoring of dalbavancin concentrations.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
586.74 kB
Formato
Adobe PDF
|
586.74 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.